The iLet Experience Study for Type 1 Diabetes
This study is looking at how well the iLet Dosing Decision Software works in real life for people with type 1 diabetes. You can join if you are at least 6 years old, have type 1 diabetes, and are using or planning to use the iLet Bionic Pancreas System with specific insulins like U100 Novolog, U100 Humalog, or U100 Fiasp® PumpCart®. The main goal is to see if the iLet system helps prevent severe hypoglycemia (very low blood sugar) and cognitive impairment (problems with thinking) over one year. The study will also compare outcomes to other studies and look at any device issues. The current status of this study is unclear.
- Study design
- This is an observational study following 1875 participants over one year to see how the iLet Dosing Decision Software performs in real-world use.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants will be followed for 12 months, with severe hypoglycemia/cognitive impairment measured at 1 year.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
The iLet Experience Study
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Steven J Russell, MD, PhD · PRINCIPAL_INVESTIGATOR · Beta Bionics
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- Severe Hypoglycemia/cognitive impairment1 year
Number of severe hypoglycemia events associated with cognitive impairment requiring the assistance of a third party for treatment per 100 patient years